ALX Oncology Holdings (ALXO) EBITDA margin US GAAP (year values) |
|||||||
| 2018 | 2019 | 2020 | LTM ? | CAGR 5 years ? | |||
| EBITDA margin, % | ? | -641.3% | -391.1% | -3 677% | |||
| Changes by years, y/y, % | +250pp | -3 286pp | +139.5% | ||||
ALX Oncology Holdings. EBITDA margin, %
ALX Oncology Holdings. EBITDA margin, changes, pp
ALX Oncology Holdings (ALXO) EBITDA margin US GAAP (quarter values) |
||||||||
| 2019Q4 | 2020Q1 | 2020Q2 | 2020Q3 | 2020Q4 | LTM ? | |||
| EBITDA margin, % | ? | -628.4% | -782.0% | -2 090% | -1 843 600 000% | |||
| Changes by years, y/y, % | -1 843 599 372pp | |||||||
| Changes by quarters, q/q, % | -154pp | -1 308pp | +2 090pp | |||||